# Nilotinib

## General description

Nilotinib is a BCR-ABL tyrosine kinase inhibitor used in treatment protocols for chronic myeloid leukaemia

| | |
|---|---|
| **INN** | Nilotinib |
| **ATC codes** | L01EA03 |
| **Medicine type** | Chemical agent |
| **EML status history** | First added in 2017 (TRS 1006) for Chronic myelogenous leukaemia, BCR-ABL1-positive |
| **Wikipedia** | Nilotinib |
| **DrugBank** | Nilotinib |

## Recommendations

**Section** Targeted therapies

- Oral > Solid > capsule: 150 mg; 200 mg

**Indications**

Chronic myelogenous leukaemia, BCR-ABL1-positive